Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.14
-0.05 (-0.61%)
At close: Nov 20, 2024, 4:00 PM
8.23
+0.09 (1.11%)
Pre-market: Nov 21, 2024, 7:14 AM EST
Iovance Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 90.86 | 1.19 | - | - | - | - | |
| Cost of Revenue | 82.82 | 10.76 | - | - | - | - | |
| Gross Profit | 8.04 | -9.57 | - | - | - | - | |
| Selling, General & Admin | 140.42 | 106.92 | 104.1 | 83.66 | 60.21 | 40.85 | |
| Research & Development | 297.58 | 344.08 | 294.78 | 259.04 | 201.73 | 166.02 | |
| Operating Expenses | 438 | 450.99 | 398.88 | 342.7 | 261.94 | 206.87 | |
| Operating Income | -429.96 | -460.56 | -398.88 | -342.7 | -261.94 | -206.87 | |
| Interest & Investment Income | 4.6 | 9.44 | 3.46 | 6.46 | 4.22 | 5.9 | |
| EBT Excluding Unusual Items | -425.36 | -451.12 | -395.42 | -336.24 | -257.72 | -200.98 | |
| Gain (Loss) on Sale of Investments | 9.22 | 3.61 | -0.47 | -6.01 | -1.87 | 3.42 | |
| Pretax Income | -416.14 | -447.52 | -395.89 | -342.25 | -259.58 | -197.56 | |
| Income Tax Expense | -6.15 | -3.48 | - | - | - | - | |
| Net Income | -410 | -444.04 | -395.89 | -342.25 | -259.58 | -197.56 | |
| Net Income to Common | -410 | -444.04 | -395.89 | -342.25 | -259.58 | -197.56 | |
| Shares Outstanding (Basic) | 278 | 235 | 159 | 153 | 138 | 124 | |
| Shares Outstanding (Diluted) | 278 | 235 | 159 | 153 | 138 | 124 | |
| Shares Change (YoY) | 30.80% | 47.64% | 3.82% | 10.92% | 11.23% | 27.82% | |
| EPS (Basic) | -1.48 | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 | |
| EPS (Diluted) | -1.48 | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 | |
| Free Cash Flow | -374.08 | -384.11 | -313.18 | -265.52 | -251.93 | -165.81 | |
| Free Cash Flow Per Share | -1.35 | -1.63 | -1.97 | -1.73 | -1.82 | -1.33 | |
| Operating Margin | -473.22% | -38734.99% | - | - | - | - | |
| Profit Margin | -451.25% | -37345.42% | - | - | - | - | |
| Free Cash Flow Margin | -411.72% | -32305.30% | - | - | - | - | |
| EBITDA | -408.32 | -449.01 | -389.57 | -339.59 | -260.8 | -205.7 | |
| D&A For EBITDA | 21.64 | 11.55 | 9.31 | 3.11 | 1.14 | 1.17 | |
| EBIT | -429.96 | -460.56 | -398.88 | -342.7 | -261.94 | -206.87 | |
| Revenue as Reported | 90.86 | 1.19 | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.